美托咪定-瓦替诺沙（Zenalpha）会导致健康犬的收缩功能减弱、血压降低、心率减慢，并延长心电图间期。 机翻

中文关键词（术语机标，非人工翻译）：心脏病 · 美托咪定 · 麻醉与镇痛 · 客户沟通与行医

摘要

To determine the effects of medetomidine-vatinoxan (Zenalpha; MVZ) on echocardiographic parameters, blood pressure, and cardiac rhythm in healthy dogs.

Healthy, client-owned dogs were eligible for enrollment in this prospective, pretest/posttest study. Exclusion criteria included preexisting cardiac disease or medications that could alter the measured study parameters. Echocardiography, blood pressure, and 1-hour Holter monitor were performed at baseline and after sedation with MVZ per the manufacturer's guidelines. Multiple echocardiographic parameters, blood pressure, and arrhythmic burden score were assessed with pairwise comparisons between baseline and sedation.

21 dogs were enrolled in the study. Compared to baseline, MVZ resulted in significant reduction in multiple echocardiography-derived systolic function parameters (including ejection fraction, fractional shortening, end-systolic volume index, stroke volume index, and fractional area change), blood pressure, and heart rate, along with prolongation in PR and absolute QT intervals; there were nonsignificant increases in corrected QT interval and arrhythmic burden scores. Thirteen of 21 dogs (62%) developed or had worsening of atrioventricular nodal conduction on Holter monitor, while 2 of 21 (9.5%) developed or had worsening atrial or ventricular ectopic activity. Of all measured echocardiographic systolic function parameters, 15 of 21 dogs (71.4%) had 2 or more parameters below reference range with MVZ sedation.

Sedation with MVZ resulted in significant changes to multiple cardiovascular and hemodynamic parameters.

The cardiovascular effects of MVZ should be considered prior to sedation in dogs with, or being screened for, cardiovascular disease.

摘要为 PubMed/NLM 公开许可元数据；全文版权归出版方所有，本平台不存储、不转载。